Mabwell (Shanghai) Bioscience Co., Ltd., (SHA: 688062) has announced the renewal of its strategic research partnership with Fudan University Shanghai Cancer Center. The collaboration, initiated in July 2021, focuses on advancing research cooperation, nurturing talent, enhancing hospital management, and constructing robust platforms for scientific exchange.
The partnership has seen significant progress with multiple clinical studies currently in various stages at the Shanghai Cancer Center. The renewed partnership is poised to expand the scope of collaboration into the realms of antibody drug conjugates (ADCs) and tumor immunotherapy.With the contract renewal, Mabwell and Fudan University Shanghai Cancer Center are committed to jointly pushing the boundaries of clinical oncology and translational medicine research.- Flcube.com
